ELITech MDx
in Molecular Diagnostics
ELITech MDx offers advanced, flexible, and automated PCR diagnostic solutions.
Bruker Expands Molecular Diagnostics with ELITechGroup Acquisition
The global fight against infectious diseases demands continuous innovation in diagnostic accuracy, speed, and reliability. With the acquisition of ELITechGroup Molecular (ELITech MDx) in 2024, Bruker strategically expands its Clinical Microbiology and Infection Diagnostics business, establishing a leading portfolio in molecular diagnostics (MDx).
ELITech MDx uniquely addresses critical diagnostic needs through advanced, fully automated sample-to-result (S2R) PCR platforms. Since pioneering the industry’s first fully integrated system in 2016, ELITech MDx has continually strengthened its technological leadership. Today, it offers nearly 50 CE-IVD-certified assays and has validated its systems across more than 20 different clinical sample matrices; including whole blood, plasma, cerebrospinal fluid, and respiratory specimens.
This exceptional flexibility empowers laboratories worldwide to consolidate molecular testing onto a single, streamlined platform, significantly improving efficiency and diagnostic accuracy.
Bruker’s innovative LiquidArray® syndromic panels, targeting complex and specialty infectious diseases including mycobacteria and gastrointestinal pathogens, complement ELITech MDx’s comprehensive PCR-based assay portfolio. This combined diagnostic ecosystem delivers an unmatched breadth and depth of testing capabilities, enabling precise pathogen detection, rapid clinical decisions, and optimized patient care.
Further enhancing this synergy, the integration of ELITech MDx aligns seamlessly with Bruker’s industry-leading MALDI Biotyper® platform-an established benchmark for rapid microbial identification. Together, these technologies offer a powerful, end-to-end diagnostic solution covering the complete spectrum from early infection detection to detailed pathogen characterization, essential for targeted treatment and effective disease management.
With over 1,400 ELITech MDx platforms installed globally and more than 12,000 tests executed daily across 60 countries, Bruker is now uniquely positioned to drive sustained innovation and leadership in infectious disease diagnostics. This comprehensive approach not only enhances laboratory productivity and clinical effectiveness but also contributes significantly to improving patient outcomes worldwide.